Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Eli Lilly's (LLY) popular weight-loss drug Zepbound outperformed Wegovy, a competitor drug from Danish drugmaker Novo Nordisk (NVO), according to the results of a new clinical study released Wednesday.

Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial

On average, Zepbound led to a superior weight loss of 20.2% compared to 13.7% with Wegovy, Lilly said.

Eli Lilly's Weight-Loss Drug Zepbound Is Better than Novo's Wegovy, Study Finds

Eli Lilly said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the two weekly injections.  The findings suggest Zepbound may be a superior treatment for weight loss, helping patients with obesity or who are overweight lose 20.2% of their body weight on average after 72 weeks.

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

Novavax

COVID-19 vaccine maker Novavax said on Wednesday it will sell its manufacturing facility in Czech Republic to Wegovy-maker Novo Nordisk for $200 million and use the proceeds for its vaccine pipeline.

Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln

Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared.  However, the Danish pharmaceutical Novo Nordisk began because of more personal reasons.

Novo-Nordisk Stock (NVO), An Investors Love Story

On Tuesday, Defiance ETFs introduced NVOX, the first single-stock leveraged ETF focused on Danish pharmaceutical giant Novo Nordisk A/S NVO.

Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum

Bagsværd, Denmark, 3 December 2024 – Novo Nordisk today announced the presentation of 13 abstracts, three of which will be presented in oral sessions, at the upcoming 66th Annual Meeting and Exposition of the American Society of Hematology (ASH), which will take place from 7 to 10 December 2024 in San Diego, California.

Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting

AstraZeneca

Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan's latest research. With concerns over US drug pricing policies easing and significant patent expirations on the horizon, the focus shifts to pipeline progress to drive growth, the American investment bank reckons, And it says Novo Nordisk (NYSE:NVO) and AstraZeneca PLC (LSE:AZN) are set to lead the way, bolstered by strong mid-term growth and promising news flow.

Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why

MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs today launched NVOX, the world's first single-stock leveraged ETF for the pharmaceutical stock Novo Nordisk (NYSE: NVO). As the weight loss market continues to expand and Novo Nordisk is a key provider in that space, NVOX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Novo Nordisk without the need for a margin account.

Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk

Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of its popular weight-loss drug Wegovy over fears of falling behind rival Eli Lilly in the potentially huge market, two sources familiar with the plans told Reuters.

Exclusive: Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms

Data from their most serious competitor, Amgen, suggests the biotech won't upstage the market leaders.

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger

General Motors

Macy's

Here are some of the major companies whose stocks moved on the week's news.

The Score: GM, Macy's, Novo Nordisk and More Stocks That Defined the Week

Few companies garner as much reliable attention as Novo Nordisk (NVO) does these days. With a bull market coinciding with a historic run of growth for the Danish pharmaceutical giant related to its GLP-1 drugs, it's no surprise that its share prices have nearly doubled over the last three years.

Is Novo Nordisk Stock a Buy?

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesday.

Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack

Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's dominance in the weight-loss drug sector. Novo's $16.5 billion acquisition of Catalent aims to alleviate supply issues, with EU antitrust approval likely, enhancing Wegovy's production capacity.

Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the year. Management expects CagriSema to generate 25% weight loss after 68 weeks of treatment. Based on the mechanism of action and phase 2 results in obese patients and type 2 diabetes patients, I agree and expect CagriSema to generate 24-27% weight loss.

Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?

Catalent

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent , a person with direct knowledge of the matter said on Friday.

EU antitrust regulators set to okay $16.5 bln Novo Holdings, Catalent deal, source says

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.

Novo Nordisk Plunges 25% in 3 Months: How to Play the Stock

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs. The post Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?

Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source familiar with the matter has told Reuters.

Ypsomed will make injection pens for Novo Nordisk's CagriSema, says source

Pfizer

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?

PFE vs. NVO: Which Stock Is the Better Value Option?

In today's article I will try to answer the question on whether the two premier diet drug companies stocks have finally stopped going down? I will look at two stocks (dietary drug is in parenthesis): Novo Nordisk NYSE:NVO (Wegovy) and Eli Lilly NYSE:LLY (Zepbound) Today I read this: WEIGHT-LOSS DRUG COVERAGE RISES AMONG LARGE US

Are Dietary Drug Stocks Eli Lilly and Novo Nordisk Ready To Rise Again?

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Is Novo Nordisk Stock a Buy Right Now?

The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will cost about $193 for a one-month supply of the lowest starter dose.

Novo Nordisk Launches Wegovy Weight-Loss Drug in China

Bagsværd, Denmark, 19 November 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

News for Novo Nordisk Stock (NVO)